NCT04747431CompletedPhase 1/2
Phase 1b Study to Assess the Safety, Tolerability and Pharmacodynamics of PBFT02 in Adult Participants with Frontotemporal Dementia (FTD) and GRN or C9orf72 Mutations
Source: EU CTIS (euclinicaltrials.eu) · Last updated 15 May 2026
- Status (registry)
- Completed
- Phase (registry)
- Phase 1/2
- Study type
- Interventional
- Enrollment
- 4 (actual)
- First submitted
- 31 Aug 2023
- Start date
- 1 Feb 2024
- Lead sponsor
- Passage Bio Inc.
- Diseases
- Frontotemporal dementia
- NCT number
- NCT04747431
- EU CT number
- 2023-507724-23-00
- EudraCT number
- 2020-004499-17
What you commit to
- Study type: Interventional · Phase 1/2
- Participants enrolled: 4
- 3 sites in 2 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study, not your situation.
Sites (3)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Hospital Universitario Central De Asturias Coordinator of this site? Confirm its status | Oviedo | Spain | Completed |
| University Hospital Virgen Del Rocio S.L. Coordinator of this site? Confirm its status | Sevilla | Spain | Completed |
| Unidade Local de Saúde de Coimbra, E.P.E. Coordinator of this site? Confirm its status | Coimbra | Portugal | Completed |
This page is information, not medical advice. Discuss any trial with your doctor.